Source comparison
PT-141 HSDD: Efficacy Comparison
PT-141 (bremelanotide) MC4R agonist. Central desire pathway activation 25–30% meaningful improvement vs 17% placebo 60–90 minutes post-injection, 4–6 hour duration Nausea 40%, transient hypertension 5%, hyperpigmentation 1–3% Best for central HSDD with intact
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist. Central desire pathway activation
- 25–30% meaningful improvement vs 17% placebo
- 60–90 minutes post-injection, 4–6 hour duration
- Nausea 40%, transient hypertension 5%, hyperpigmentation 1–3%
- Best for central HSDD with intact hormones; requires tolerance to acute nausea
- Flibanserin (Addyi)
- 5-HT1A agonist, 5-HT2A antagonist. Chronic serotonin modulation
- 9–13% meaningful improvement vs placebo
- Daily dosing required; effects emerge after 4–8 weeks
- Dizziness 11%, somnolence 11%, hypotension with alcohol contraindicated
- Requires daily adherence; modest effect size; alcohol interaction limits use
- Testosterone replacement (off-label)
- Androgen receptor activation. Peripheral and central effects
- 30–40% improvement in surgical menopause; minimal effect in premenopausal HSDD
- 2–4 weeks for subjective changes
- Acne, hirsutism, voice deepening with supraphysiologic doses
- Effective in androgen deficiency states; not FDA-approved for HSDD
- Estrogen + counselling
- Peripheral tissue sensitivity + psychoeducation
- Variable. Effective for atrophy-related pain, limited effect on central desire
- 4–12 weeks for tissue effects
- Vaginal bleeding, breast tenderness, thromboembolic risk with systemic estrogen
- Addresses dyspareunia and relationship factors; does not target central desire
- PT-141 occupies a specific clinical niche: premenopausal women with acquired, generalised HSDD who have normal estrogen and testosterone levels but suppressed central motivation. It does not address genitopelvic pain, relationship conflict, medication-induced dysfunction (SSRIs), or situational desire loss. The 25% response rate is statistically significant but clinically modest. Three-quarters of treated patients do not achieve meaningful improvement. Patient selection determines outcome: women with clear central desire deficits and intact peripheral function respond better than those with mixed presentations.